Page 762 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

746 Index

Chronic leukemias, 372 Clonal, 417 Con dence/control limits, 18
Chronic lymphocytic leukemia (CLL)/small Clonal hematopoietic disorders Congenital amegakaryocytic thrombocytopenia

lymphocytic lymphoma (SLL), 190 acute myelogenous leukemia (AML), 518 (CAM ), 252–253
allogeneic hematopoietic stem cell MDS, 518 Congenital dyserythropoietic anemia (CDA),
transplantation (alloHSC ), 421 myeloproli erative disorders (MPNs), 250–251
classi cation, 416, 417t 518–519 physiology, 251

clinical signs and symptoms, 419 Clonality, 654 telomeres impact, 251
cytogenetics, 416 Clot wave orm analysis (CWA), 536 types, 250–251
decision to treat, 420 Clotting assay method, antithrombin III, 694–695 Congenital plasminogen de ciency, 574
epidemiology, 416 Cluster o dif erentiation (CD), 59, 198 Conjugated bilirubin, 132

etiology, 416, 416b CML (see Chronic myelogenous leukemia) Consolidation therapy, 397
historical treatments, 420–421 CMML (see Chronic myelomonocytic leukemia) Constitutional aplastic anemia, 244, 248–249
laboratory data, 419, 420, 420b, 421 Coagulation actor assays Constitutional bone marrow ailure syndromes
minimal residual disease, 422 brinogen group dyskeratosis congenita, 249

molecular genetics actor I ( brinogen), 557 Fanconi anemia, 248–249
Cd38, 418 actor V (labile actor), 557 Contact group, 528, 558
microRNA, 418, 421 actor XIII A/ actor XIII B ( brin stabilizing Core-binding actor (CBF) complex-, 386
thymidine kinase, 418 actor), 557–558 Coverslip method, blood lm preparation, 46

variable-region genes, 417–418 laboratory screening tests, 557t Cryo brinogenemia, 507
zeta-chain-associated protein 70 prothrombin group Cryoglobulinemia vasculitis, 506
(ZAP-70), 418 actor II (prothrombin), 558 Cryoglobulins, 441
newer treatments, 421 actor VII (labile actor), 558 Crystalline inclusions, lymphocytes, 196

staging and prognosis, 418–419, 419t actor X, FX (stuart-prower actor), 558 Cumulative sum (Cusum) method, 18–19
Chronic lymphocytosis actor XI, 558–559 Cutaneous -cell lymphoma (C CL)
adult -cell leukemia/lymphoma, 425, 426 actor XII (hageman actor), 559 Mycosis ungoides, 424, 424–425, 425
B-cell prolymphocytic leukemias, 422 high molecular weight kininogen de ciency Sézary syndrome, 424–425, 425

CLL/SLL, 416–421, 416b, 417t, 419t, 420, 421 (HMWK) de ciency, 559 Cyanmethemoglobin method, 130
cutaneous -cell lymphoma, 424, Prekallikrein de ciency, 559 Cyclic neutropenia, 251–252
424–425, 425 Coagulation inhibitor, 533 Cytochemical staining method
hairy cell leukemia, 422–423, 423 Coagulation pathways acid phosphatase in leukocytes, 686

mature B-Cell neoplasms, 416, 416b extrinsic coagulation pathway, 530, 530 alkaline phosphatase in leukocytes, 686–687,
monoclonal B-cell lymphocytosis, 422 brin ormation, 531 687, 687t
-cell large granular lymphocytic leukemia nal common pathway, 531 alpha-naphthyl acetate esterase with uoride
(LGL), 425, 426 intrinsic coagulation pathway, 530–531, 531 inhibition, 687–688, 688

-cell prolymphocytic leukemias, 423–424, Coagulation procedures, manual Heinz bodies, 688, 688–689
424, 424t anticoagulants, 691 naphthol as-D chloroacetate esterase, 688
Chronic myelogenous leukemia (CML) error, general sources o , 692 Periodic acid-Schif , 689, 689–690
allogeneic bone marrow transplantation, 458 procedural ormat, 670 peroxidase (myeloperoxidase), 690, 690

atypical chronic myeloid leukemia, 458, 458t quality control, 692 Sudan black B stain, 690, 690–691
CEL-NOS, 459 special collection techniques, 691 Cytochemical stains
chronic eosinophilic leukemias, 459 specimen handling, 692 esterase stains, 394, 396b
chronic neutrophilic leukemia, 458, 458t specimen preparation, 692 myeloperoxidase stain, 394, 395

cytogenetic studies, 455 specimen quality, 691 periodic acid-schif stain, 394, 395t
cytogenetics, 452, 452 Coagulation studies special cytochemical stains, 395
epidemiology, 451 electromechanical methods, 639–640, 640 Sudan black B stain, 394, 394t
genetic alterations brinolytic hemostasis panel assays, 639b Cytochemistry, 454–455

accelerated phase, 453, 453t photo-optical methods, 640 Cytogenetic analysis
blast crisis (acute), 453–454, 453t platelet agglutination, 640–641 in acute lymphoblastic leukemia, 401
chromosomal translocation, oncogene acti- platelet aggregation, 641 in acute myeloid leukemia, 385–386, 385t
vation, 452–453, 453 thrombotic hemostasis panel, 639, 639b Cytogenetics, 416, 422

gene rearrangement, 452, 452 viscosity-based detection system, 640 Cytokines
initial phase, 453, 453t Cobalamin (see Vitamin B ) colony-stimulating actors, 92
12
laboratory data Codocytes, 148, 148–149 inter eron, 92, 93t
cellular components, 454, 454 Coe cient o variation (CV), 17–18 interleukins (ILs), 93–94, 94

cytochemistry, 454–455 Colony-stimulating actor (CSF), 165 Cytokinesis, 68
leukemia-speci c targets, 457–458 Complement, hemolytic anemias, 293–295 Cytomegalovirus (CMV) in ection, 359–360
minimal residual disease, 456–457, 457 Complement-mediated disease Cytoreduction, 463
cytogenetic and molecular responses, 457, cold agglutinin disease (CAD), 307

457 paroxysmal cold hemoglobinuria, 307 D
resistance, 457 paroxysmal nocturnal hemoglobinuria (PNH), D-dimer assay, 696
pathophysiology, 452 306–307 D-dimer testing, 538–539, 539
PDGFRA-associated chronic eosinophilic Complement receptor, 178 Dacie method, 685–686

leukemia, 459 Complement system, 534 De nitive erythropoiesis, 82
prognosis and treatment, 455–456, 456 Complete blood count (CBC), 2, 94 Degmacytes, 146
Chronic myelomonocytic leukemia (CMML) erythrocytes Deletion, chromosomal, 65
atypical chronic myeloid leukemia, 484 manual cell counting, 210, 211t Delta check system, 14

characteristics o , 483b quantitative assessment, 211–216 Delta checks, 627
cytochemical staining, 484b leukocytes Delta granules, 495
juvenile myelomonocytic leukemia, 484 manual cell counting, 210, 211t Dense granules, 495
laboratory data, 483, 483 quantitative assessment, 216–218 Deoxynucleotide, 660

pathophysiology, 483 peripheral blood lm evaluation, 219–220 Deoxyribonucleic acid (DNA), 653
Circulating anticoagulants, 695–696 platelets composition, 71
Circulating pool, 166 manual cell counting, 210, 211t histone protein, 64
Citrate agar electrophoresis, 131 quantitative assessment, 218–219 location, 64

Clinical Laboratory Improvement Amendments semiquantitative grading, 220–221 structure, 67b
(CLIA), 12, 14–16 Complete molecular remission (CMR), 74 Dialysis, 59